Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Celltech Details Phase III Trial Plans For CDP870 In Crohn's

Jan. 7, 2004

By Aaron Lorenzo

A Phase III program in Crohn's disease is under way to evaluate a compound being developed by Celltech Group plc. (BioWorld International)

Millennium Halts Phase II Velcade Combination Trial In Colon Cancer

Jan. 7, 2004

By Aaron Lorenzo

Celltech Details Phase III Trial Plans For CDP870 In Crohn's

Jan. 7, 2004

By Aaron Lorenzo

Millennium Halts Phase II Velcade Combination Trial In Colon Cancer

Jan. 7, 2004

By Aaron Lorenzo

Celltech Details Phase III Trial Plans For CDP870 In Crohn's

Jan. 7, 2004

By Aaron Lorenzo

A Phase III program in Crohn's disease is under way to evaluate a compound being developed by Celltech Group plc. (BioWorld International)

Dynogen Teams Up With J&J Unit For Overactive Bladder Treatment

Jan. 6, 2004

By Aaron Lorenzo

Dynogen Teams Up With J&J Unit For Overactive Bladder Treatment

Jan. 6, 2004

By Aaron Lorenzo

Cell Therapy Deal With Amgen Worth At Least $20M To ViaCell

Jan. 5, 2004

By Aaron Lorenzo

Cell Therapy Deal With Amgen Worth At Least $20M To ViaCell

Jan. 5, 2004

By Aaron Lorenzo

Xechem Buys Ceptor, Adds Size To Niche Drug Pipeline

Dec. 31, 2003

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...